TABLE 1.
Clinical characteristics of study participants
| HCC | Control subjects | |
|---|---|---|
| Subjects (n) | 122 | 125 |
| Age, median, years | 55 | 47 |
| Sex | ||
| Male (n) | 106 (87%) | 83 (66%) |
| Female (n) | 16 (13%) | 42 (34%) |
| Liver disease | ||
| Cirrhosis, n (%) | 45 (37%) | 46 (37%) |
| Chronic HBV, n (%) | 88 (72%) | 72 (58%) |
| Chronic HCV, n (%) | 3 (3%) | 4 (3%) |
| Fatty liver disease, n (%) | 1 (1%) | 20 (16%) |
| Other a , n (%) | 34 (28%) | 26 (21%) |
| Protein tumor markers | ||
| AFP, median (ng/mL) | 65.8 | 1.7 |
| AFP‐L3%, median (%) | 10% | <5% |
| DCP, median (ng/mL) | 13.8 | 0.6 |
| GALAD | 2.76 | −4.52 |
| Stage | ||
| I | 29 (24%) | |
| II | 8 (7%) | |
| III | 43 (35%) | |
| IV | 28 (23%) | |
| Unstaged or unknown | 14 (12%) |
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus.
a
Other liver conditions include liver cysts and benign liver tumors.